IN2014MN01989A - - Google Patents

Info

Publication number
IN2014MN01989A
IN2014MN01989A IN1989MUN2014A IN2014MN01989A IN 2014MN01989 A IN2014MN01989 A IN 2014MN01989A IN 1989MUN2014 A IN1989MUN2014 A IN 1989MUN2014A IN 2014MN01989 A IN2014MN01989 A IN 2014MN01989A
Authority
IN
India
Prior art keywords
hepatitis
treatment
determining whether
sample
methods
Prior art date
Application number
Inventor
Hendrik Willem Reesink
Louis Jansen
Neeltje Akke Kootstra
Original Assignee
Amc Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amc Amsterdam filed Critical Amc Amsterdam
Publication of IN2014MN01989A publication Critical patent/IN2014MN01989A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides means and methods for determining whether a hepatitis B patient is susceptible to hepatitis B treatment comprising determining whether a sample of the patient comprises nucleic acid with nucleotide polymorphisms that are associated with a positive outcome of hepatitis B treatment and/or determining whether a sample of the patient comprises an expression level of carnitine or of a carnitine derivative that is associated with a positive outcome of hepatitis B treatment. Compositions kits of parts (micro)arrays and vectors useful for such methods are also herewith provided.
IN1989MUN2014 2012-03-19 2013-03-19 IN2014MN01989A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12160199 2012-03-19
EP12186188 2012-09-26
PCT/NL2013/050204 WO2013141705A2 (en) 2012-03-19 2013-03-19 Means and methods for response prediction of hepatitis b treatment

Publications (1)

Publication Number Publication Date
IN2014MN01989A true IN2014MN01989A (en) 2015-07-10

Family

ID=47997743

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1989MUN2014 IN2014MN01989A (en) 2012-03-19 2013-03-19

Country Status (9)

Country Link
US (2) US20150044167A1 (en)
EP (1) EP2828401B1 (en)
BR (1) BR112014023296A2 (en)
ES (1) ES2657266T3 (en)
HK (1) HK1206791A1 (en)
IN (1) IN2014MN01989A (en)
MX (1) MX2014011256A (en)
RU (1) RU2640256C2 (en)
WO (1) WO2013141705A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160091354A (en) * 2013-12-17 2016-08-02 에프. 호프만-라 로슈 아게 Biomarkers for hbv treatment response
JP2018519839A (en) * 2015-07-15 2018-07-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Biomarkers for HBV treatment response
CN109504763B (en) * 2018-12-17 2020-09-04 北京三元基因药业股份有限公司 Molecular marker for predicting efficacy of interferon-alpha for treating hepatitis B patients
TW202039473A (en) 2018-12-19 2020-11-01 丹麥商理奧藥品公司 Small molecule modulators of il-17
CN115267193B (en) * 2022-09-20 2022-12-27 北京大学 Method, system and application for judging source of HBsAg in biological sample

Also Published As

Publication number Publication date
BR112014023296A2 (en) 2019-09-24
WO2013141705A2 (en) 2013-09-26
EP2828401A2 (en) 2015-01-28
US20150044167A1 (en) 2015-02-12
RU2640256C2 (en) 2017-12-27
WO2013141705A3 (en) 2013-12-05
US20180044735A1 (en) 2018-02-15
EP2828401B1 (en) 2017-10-25
HK1206791A1 (en) 2016-01-15
RU2014142009A (en) 2016-05-10
MX2014011256A (en) 2015-07-14
ES2657266T3 (en) 2018-03-02

Similar Documents

Publication Publication Date Title
HK1250245A1 (en) Spatially distinguished, multiplex nucleic acid analysis of biological specimens
MX365323B (en) Nuclei acid amplification.
MX2016007541A (en) Modified nucleic acid molecules and uses thereof.
MX2014003979A (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof.
WO2015196128A3 (en) Alternative nucleic acid molecules and uses thereof
WO2015196130A3 (en) Alternative nucleic acid molecules and uses thereof
EP3161162A4 (en) Analysis of nucleic acid sequences
EA201590488A1 (en) METHODS OF MODIFICATION OF CELL-OWNERS
MX2017007731A (en) Detergent compositions, lipase variants and polynucleotides encoding same.
EP3161160A4 (en) Methods of analyzing nucleic acids from individual cells or cell populations
GB2537077A (en) Methods for sequencing nucleic acids
MX367666B (en) Compositions and methods for quantifying a nucleic acid sequence in a sample.
EA201690529A1 (en) METHODS OF MODIFICATION OF CELL-HOST
EA201692157A1 (en) SYNTHESIS OF TWO-CELLULAR NUCLEIC ACIDS
IN2014DN08573A (en)
MX2021013104A (en) Lipase variants and polynucleotides encoding same.
IN2014MN01989A (en)
EP3368654A4 (en) Determination of polymorphisms using isothermal nucleic acid amplification
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
WO2014003583A8 (en) Detection of pathogens
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
MX2018005872A (en) Nucleic acid prodrugs.
IN2014CN03187A (en)
MX370616B (en) Nucleic Acid Amplification.
MX366113B (en) Diagnostic methods and compositions.